Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

MediWound (MDWD) Research & Development (2016 - 2025)

MediWound has reported Research & Development over the past 13 years, most recently at $4.5 million for Q4 2025.

  • For Q4 2025, Research & Development rose 49.97% year-over-year to $4.5 million; the TTM value through Dec 2025 reached $14.3 million, up 61.3%, while the annual FY2025 figure was $14.3 million, 61.3% up from the prior year.
  • Research & Development for Q4 2025 was $4.5 million at MediWound, up from $3.5 million in the prior quarter.
  • Over five years, Research & Development peaked at $4.5 million in Q4 2025 and troughed at $1.5 million in Q1 2024.
  • A 5-year average of $2.6 million and a median of $2.5 million in 2021 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: tumbled 46.83% in 2023 and later soared 96.33% in 2025.
  • Year by year, Research & Development stood at $2.5 million in 2021, then rose by 9.67% to $2.7 million in 2022, then plummeted by 33.01% to $1.8 million in 2023, then surged by 65.15% to $3.0 million in 2024, then soared by 49.97% to $4.5 million in 2025.
  • Business Quant data shows Research & Development for MDWD at $4.5 million in Q4 2025, $3.5 million in Q3 2025, and $3.5 million in Q2 2025.